Neonatal methylphenidate does not impair adult spatial learning in the Morris water maze in rats

University of Cincinnati, Cincinnati, Ohio, United States
Neuroscience Letters (Impact Factor: 2.06). 07/2011; 502(3):152-6. DOI: 10.1016/j.neulet.2011.07.013
Source: PubMed

ABSTRACT Methylphenidate (MPD) is the most prescribed drug for attention deficit hyperactivity disorder. Licit and illicit use also occurs during pregnancy, however the effects from this use on offspring development are unknown. To model late gestational exposure, Sprague-Dawley litters were treated with 0, 5, 10, 20, or 30mg/kg×4/day every 2h with MPD on postnatal days 11-20 (within-litter design; days chosen to be comparable to human third trimester brain development). During treatment, body weights were decreased in MPD-treated groups; weight recovery occurred in all but the MPD-30 group by start of testing. MPD-treated rats showed no changes in anxiety (elevated zero maze), swimming ability (straight channel swimming), or spatial learning/reference memory (Morris water maze). MPD does not appear to pose a risk to these CNS functions after exposure during a stage of rat development analogous to third trimester human brain development.

1 Bookmark
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The psychostimulant methylphenidate (MPD) is a first-line drug for the treatment of attention deficit hyperactivity disorder (ADHD). Despite acceptable therapeutic efficacy, there is limited data regarding the long-term consequences of MPD exposure over extended periods. The present study concerns effects of clinically relevant doses of MPD, administered orally to rats for an extended period, on spatial memory, behavioral sensitization and habituation to an open field. Water maze test was used to monitor memory acquisition (2h after training), retention (day next to training), extinction (one week after training) and reconsolidation (weekly for 4 weeks). Administration of MPD at doses of 0.25-1.0mg/kg improved memory acquisition, retention, reconsolidation and impaired memory extinction. Treatment with 0.25 and 0.5mg/kg MPD for 6 weeks produced a sustained increase in motor activity but higher dose (1.0mg/kg) elicited behavioral sensitization. High as well as low doses MPD impaired open field habituation. We conclude that clinically relevant doses of MPD enhance memory even if used for extended period. It is suggested that higher (1.0mg/kg) clinically relevant doses of MPD, if used for extended period, may exacerbate hyperactivity and impulsivity associated with the disease. Copyright © 2014. Published by Elsevier B.V.
    Behavioural Brain Research 12/2014; 281. DOI:10.1016/j.bbr.2014.12.031 · 3.39 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The widespread usage of methylphenidate (MPH) in the pediatric population has received considerable attention due to its potential effect on child development. For the first time a physiologically based pharmacokinetic (PBPK) model has been developed in juvenile and adult humans and nonhuman primates to quantitatively evaluate species- and age-dependent enantiomer specific pharmacokinetics of MPH and its primary metabolite ritalinic acid. The PBPK model was first calibrated in adult humans using in vitro enzyme kinetic data of MPH enantiomers, together with plasma and urine pharmacokinetic data with MPH in adult humans. Metabolism of MPH in the small intestine was assumed to account for the low oral bioavailability of MPH. Due to lack of information, model development for children and juvenile and adult nonhuman primates primarily relied on intra- and interspecies extrapolation using allometric scaling. The juvenile monkeys appear to metabolize MPH more rapidly than adult monkeys and humans, both adults and children. Model prediction performance is comparable between juvenile monkeys and children, with average root mean squared error values of 4.1 and 2.1, providing scientific basis for interspecies extrapolation of toxicity findings. Model estimated human equivalent doses in children that achieve similar internal dose metrics to those associated with pubertal delays in juvenile monkeys were found to be close to the therapeutic doses of MPH used in pediatric patients. This computational analysis suggests that continued pharmacovigilance assessment is prudent for the safe use of MPH.
    PLoS ONE 09/2014; 9(9):e106101. DOI:10.1371/journal.pone.0106101 · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Researchers have observed unsustainable neurogenesis of the dentate gyrus of the hippocampus, as well as cognitive improvements in short-term imipramine-treated mice following a controlled cortical impact (CCI) model of traumatic brain injury (TBI). But they have yet to investigate the effects of a longer-duration imipramine treatment. In this study, we investigated the effects of a longer treatment regimen on rats following a fluid percussion injury (FPI) model, which creates a brain injury that more closely resembles those incurred by human patients. We administered imipramine to rats for 8 weeks following FPI. Brain histology was performed to measure neurogenesis and cognitive recovery was evaluated using the Morris water maze (MWM). The Injury+imipramine group demonstrated 172% neurogenesis relative to the injury alone group at 9+ weeks in the dentate gyrus of the hippocampus. Neurogenesis observed here involved both the injured and the uninjured sides of the brain. All four groups (FPI+imipramine, FPI, sham, sham+imipramine) showed a similar performance in the MWM task. Longer duration of treatment with imipramine promotes sustained increase in hippocampal cell proliferation and survival. Global neurogenesis corresponds to the diffuse nature of FPI injury. Cognitive outcome can be due to a delay in our behavior testing as much as an absence of cognitive benefit of imipramine at this stage of neurogenesis. Nevertheless, exploring the potential benefits of prophylactic antidepressant treatment in human TBI patients is worthwhile.
    Neurological Research 04/2013; 35(3):247-54. DOI:10.1179/1743132813Y.0000000164 · 1.45 Impact Factor

Full-text (2 Sources)

Available from
May 27, 2014